

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Ocumention Therapeutics**  
**歐康維視生物**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1477)**

**INSIDE INFORMATION**  
**INCLUSION OF OT-401 IN CHINA NATIONAL REIMBURSEMENT**  
**DRUG LIST**

This announcement is made by Ocumention Therapeutics (the “**Company**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Future Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors of the Company is pleased to announce that OT-401 (YUTIQ, product name: Youshiying (優施瑩)), the core product of the Company, has been successfully included in the updated National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2023 Version) (“**NRDL**”) issued by the China National Healthcare Security Administration (the “**NHSA**”) for the approved indication of chronic non-infectious uveitis, according to the announcement from the NHSA on December 13, 2023. The updated NRDL will officially take effect on January 1, 2024.

OT-401 (YUTIQ) is a first-in-class, innovative injectable, sustained-release micro-insert for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye in-licensed from EyePoint Pharmaceuticals, Inc. OT-401 is a sterile non-bioerodible intravitreal implant designed to provide sustained release of a total of 0.18mg of the active ingredient fluocinolone acetonide, a corticosteroid, at a controlled rate for up to 36 months from a single administration performed in an outpatient visit. To date, YUTIQ is the first and only uveitis treatment designed to deliver fluocinolone for up to 36 months that has been approved by the United States Food and Drug Administration (FDA).

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Ocumension Therapeutics**  
**Dr. Lian Yong CHEN**  
*Chairman and Non-executive Director*

Hong Kong, December 13, 2023

*As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive directors, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive directors.*